SAGE Therapeutics, Inc.

... ...
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc. 0.02%26.3814.1%$155.22m
HZNPHorizon Therapeutics Plc 0.00%78.725.6%$155.02m
CTLTCatalent, Inc. 0.00%115.502.1%$100.92m
BHCBausch Health Cos., Inc. 0.02%26.380.0%$97.36m
JAZZJazz Pharmaceuticals Plc 0.00%167.712.4%$85.03m
UTHRUnited Therapeutics Corp. 0.00%172.8214.1%$65.27m
ACSTAcasti Pharma, Inc. 0.00%0.600.2%$56.03m
ISRIsoRay, Inc. -1.52%1.952.5%$50.08m
PRGOPerrigo Co. Plc -0.05%43.696.8%$49.79m
GWPHGW Pharmaceuticals Plc 0.00%135.736.1%$48.72m
SAGESAGE Therapeutics, Inc. 0.00%91.387.6%$48.72m
AMRNAmarin Corp. Plc 0.00%6.071.5%$48.42m
ICLRICON plc 0.00%210.354.2%$39.35m
TNXPTonix Pharmaceuticals Holding Corp. 0.00%0.910.2%$37.77m
ENDPEndo International Plc 0.00%7.128.7%$36.76m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.